LegisTrack
Back to all bills
SRES 194119th CongressIn Committee

A resolution expressing support for the designation of the month of April 2025 as "Parkinson's Awareness Month".

Introduced: Apr 30, 2025
Standard Summary
Comprehensive overview in 1-2 paragraphs

This is a Senate resolution (S. Res. 194) introduced in the 119th Congress that expresses support for designating April 2025 as “Parkinson’s Awareness Month.” The resolution highlights the scale and impact of Parkinson’s disease in the United States, emphasizes the need for continued research, education, and community support, and recognizes the contributions of people living with Parkinson’s, clinical trial participants, caregivers, researchers, and advocacy organizations. It is a ceremonial, non-funding measure intended to promote awareness and ongoing commitment to finding better treatments and a cure, rather than to authorize new programs or spending. The bill notes that Parkinson’s affects over 1 million people in the U.S. (with about 90,000 new diagnoses each year), is a leading neurodegenerative disease, can have a wide range of symptoms (movement problems, cognitive issues, speech/swallowing difficulties, mood disorders, etc.), and carries a substantial societal and economic burden (costs projected to at least $80 billion annually, with numbers rising). It also points to the importance of clinical trials and the broader network of families, volunteers, and researchers working to improve lives.

Key Points

  • 1The Senate expresses support for designating April 2025 as “Parkinson’s Awareness Month.”
  • 2It supports the goals and ideals of Parkinson’s Awareness Month, including education, awareness, and advocacy activities.
  • 3It commits to continuing support for research to develop better treatments and a cure for Parkinson’s disease.
  • 4It recognizes individuals living with Parkinson’s who participate in clinical trials to advance knowledge about the disease.
  • 5It commends organizations, volunteers, researchers, and the broader public for efforts to improve quality of life for people with Parkinson’s and their families.

Impact Areas

Primary group/area affected: People living with Parkinson’s disease and their families/caregivers in the United States.Secondary group/area affected: Researchers, clinicians, and participants in Parkinson’s clinical trials; advocacy and patient-support organizations.Additional impacts: Raises awareness among the public and policymakers, potentially encouraging continued or expanded private and nonprofit support for research and education; no direct federal funding or new programs are created by this resolution.
Generated by gpt-5-nano on Oct 31, 2025